EcoDrugPlus

60s Ribosomal Protein L5-Like

Ensembl ID : ENSNBRG00000015839
Gene Symbol: LOC102781853
3 Cross references
455 Possible Orthologues:

60s Ribosomal Protein L6-Like

Ensembl ID : ENSNBRG00000019281
Gene Symbol: LOC102780500
3 Cross references
486 Possible Orthologues:

60s Ribosomal Protein L7-Like

Ensembl ID : ENSNBRG00000023780
Gene Symbol: LOC102776785
3 Cross references
492 Possible Orthologues:

60s Ribosomal Protein L8-Like

Ensembl ID : ENSNBRG00000019585
Gene Symbol: LOC102782025
3 Cross references
276 Possible Orthologues:

60s Ribosomal Protein L9-Like

Ensembl ID : ENSNBRG00000016133
Gene Symbol: LOC102787437
3 Cross references
509 Possible Orthologues:

72 Kda Type Iv Collagenase-Like

Ensembl ID : ENSNBRG00000009858
Gene Symbol: LOC102792511
3 Cross references
209 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSNBRG00000005494
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSNBRG00000004857
Gene Symbol: ADAM17
3 Cross references
210 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSNBRG00000008970
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSNBRG00000008834
Gene Symbol: ADRM1
1 Cross references
194 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSNBRG00000007488
Gene Symbol: ADRM1
1 Cross references
191 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSNBRG00000001322
Gene Symbol: AKT1
3 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).